{"id":4073,"date":"2013-08-05T00:00:00","date_gmt":"2013-08-05T04:00:00","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/journal-articles\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\/"},"modified":"2023-06-14T20:05:12","modified_gmt":"2023-06-15T00:05:12","slug":"metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\/","title":{"rendered":"Metformin use and all-cause and prostate cancer\u2013specific mortality among men with diabetes"},"content":{"rendered":"<p><strong>Purpose<\/strong> &#x2014; To evaluate the association between cumulative duration of metformin use after prostate cancer (PC) diagnosis and all-cause and PC-specific mortality among patients with diabetes.<\/p>\n<p><span class=\"bold\">Patients and Methods<\/span> &#x2014; The authors used a population-based retrospective cohort design. Data were obtained from several Ontario healthcare administrative databases. Within a cohort of men older than age 66 years with incident diabetes who subsequently developed PC, the authors examined the effect of duration of antidiabetic medication exposure after PC diagnosis on all-cause and PC-specific mortality. Crude and adjusted hazard ratios (HRs) were calculated by using a time-varying Cox proportional hazard model to estimate effects.<\/p>\n<p><strong>Results<\/strong> &#x2014; The cohort consisted of 3,837 patients. Median age at diagnosis of PC was 75 years (interquartile range [IQR], 72 to 79 years). During a median follow-up of 4.64 years (IQR, 2.7 to 7.1 years), 1,343 (35%) died, and 291 patients (7.6%) died as a result of PC. Cumulative duration of metformin treatment after PC diagnosis was associated with a significant decreased risk of PC-specific and all-cause mortality in a dose-dependent fashion. Adjusted HR for PC-specific mortality was 0.76 (95% CI, 0.64 to 0.89) for each additional 6 months of metformin use. The association with all-cause mortality was also significant but declined over time from an HR of 0.76 in the first 6 months to 0.93 between 24 and 30 months. There was no relationship between cumulative use of other antidiabetic drugs and either outcome.<\/p>\n<p><strong>Conclusion<\/strong> &#x2014; Increased cumulative duration of metformin exposure after PC diagnosis was associated with decreases in both all-cause and PC-specific mortality among diabetic men. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Purpose &#x2014; To evaluate the association between cumulative duration of metformin use after prostate cancer (PC) diagnosis and all-cause and PC-specific mortality among patients with diabetes. Patients and Methods &#x2014; The authors used a population-based retrospective cohort design. Data were obtained from several Ontario healthcare administrative databases. Within a cohort of men older than age [&hellip;]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[38,50,56],"migration-helper-qa-sample-set":[],"class_list":["post-4073","journal_article","type-journal_article","status-publish","hentry","topic-cancer-and-cancer-screening","topic-endocrinology","topic-pharmacoepidemiology-and-drug-safety"],"acf":{"citation":"Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N. <em>J Clin Oncol.<\/em> 2013; 31(25):3069-75. Epub 2013 Aug 5.","source_url":"http:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.2012.46.7043","ices_scientist":[1343,1295,1172,1147,1385,17132],"site":[6733,6735],"research_program":[6741,6746,6742],"news_release":[7438],"journal_article":[],"atlas":[],"research_report":[],"infographic":[],"video":[],"downloads":null,"links":null,"sitecore_item_id":"B8EBC500-73BF-4B7E-9A20-D53FA898D5F7","sitecore_item_name":"Metformin-use-and-all-cause-and-prostate-cancer","sitecore_field_values":"{\n  \"Title\": \"Metformin use and all-cause and prostate cancer\u2013specific mortality among men with diabetes\",\n  \"Short title\": \"Metformin use and all-cause\",\n  \"Citation\": \"<p>Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N. <em>J Clin Oncol.<\/em> 2013; 31(25):3069-75. Epub 2013 Aug 5.<\/p>\",\n  \"Abstract\": \"<p><strong>Purpose<\/strong> &mdash; To evaluate the association between cumulative duration of metformin use after prostate cancer (PC) diagnosis and all-cause and PC-specific mortality among patients with diabetes.<\/p>n<p><span class=\"bold\">Patients and Methods<\/span> &mdash; The authors used a population-based retrospective cohort design. Data were obtained from several Ontario healthcare administrative databases. Within a cohort of men older than age 66 years with incident diabetes who subsequently developed PC, the authors examined the effect of duration of antidiabetic medication exposure after PC diagnosis on all-cause and PC-specific mortality. Crude and adjusted hazard ratios (HRs) were calculated by using a time-varying Cox proportional hazard model to estimate effects.<\/p>n<p><strong>Results<\/strong> &mdash; The cohort consisted of 3,837 patients. Median age at diagnosis of PC was 75 years (interquartile range [IQR], 72 to 79 years). During a median follow-up of 4.64 years (IQR, 2.7 to 7.1 years), 1,343 (35%) died, and 291 patients (7.6%) died as a result of PC. Cumulative duration of metformin treatment after PC diagnosis was associated with a significant decreased risk of PC-specific and all-cause mortality in a dose-dependent fashion. Adjusted HR for PC-specific mortality was 0.76 (95% CI, 0.64 to 0.89) for each additional 6 months of metformin use. The association with all-cause mortality was also significant but declined over time from an HR of 0.76 in the first 6 months to 0.93 between 24 and 30 months. There was no relationship between cumulative use of other antidiabetic drugs and either outcome.<\/p>n<p><strong>Conclusion<\/strong> &mdash; Increased cumulative duration of metformin exposure after PC diagnosis was associated with decreases in both all-cause and PC-specific mortality among diabetic men. <\/p>n<p><a href=\"http:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.2012.46.7043\" title=\"Opens external link\">View full text<\/a><\/p>\",\n  \"Keywords\": \"{0970CC2D-3A0C-49B9-834C-36EA27DB42B1}|{26EB1DB1-6793-4CB3-9CFB-DFF37E09FB5A}|{B711DE54-5056-420D-AA0E-1349F1D88049}\",\n  \"Related Products\": \"<h2>News Release<\/h2>rn<h3><a href=\"~\/link.aspx?_id=F4826430E62C43BEB20EE769F6AD7AFC&amp;_z=z\">Metformin use associated with significant improvement in mortality among diabetic men with prostate cancer: study<\/a><\/h3>\",\n  \"Research Programs\": \"{85DE96A6-4C96-40C7-8E6D-7597A0EB5F80}|{CFE36C89-C969-4C23-B5E4-1BA9E5BDC273}|{BEC72DE0-BA8C-42B8-ACE5-EE29FFB2CB3B}\",\n  \"ICES Locations\": \"{4FCAABBA-14A5-42E6-8F33-BC6C2F1D9908}|{FBE2D1B1-C0BA-423F-8D16-39466B6C1424}\",\n  \"ICES Scientists\": \"{44155080-6CB5-428D-9E38-9693CAD11DD3}|{DC2C9ADE-ED70-4834-A8AC-A7271C6E48F5}|{9F60496B-63FD-4BE5-A7EF-C4969D7AACB3}|{9564D1CB-B35F-4CEC-9144-23097BB45807}|{7D498E8B-5801-4F9E-AC41-11ED50F3C34E}\",\n  \"Posted Date\": \"20130805T000000\"\n}","previous_url":"https:\/\/www.ices.on.ca\/Publications\/Journal-Articles\/2013\/January\/Metformin-use-and-all-cause-and-prostate-cancer"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICES | Metformin use and all-cause and prostate cancer\u2013specific mortality among men with diabetes<\/title>\n<meta name=\"description\" content=\"Purpose &#x2014; To evaluate the association between cumulative duration of metformin use after prostate cancer (PC) diagnosis and all-cause and\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Metformin use and all-cause and prostate cancer\u2013specific mortality among men with diabetes\" \/>\n<meta property=\"og:description\" content=\"Purpose &#x2014; To evaluate the association between cumulative duration of metformin use after prostate cancer (PC) diagnosis and all-cause and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-15T00:05:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\\\/\",\"name\":\"ICES | Metformin use and all-cause and prostate cancer\u2013specific mortality among men with diabetes\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2013-08-05T04:00:00+00:00\",\"dateModified\":\"2023-06-15T00:05:12+00:00\",\"description\":\"Purpose &#x2014; To evaluate the association between cumulative duration of metformin use after prostate cancer (PC) diagnosis and all-cause and\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Metformin use and all-cause and prostate cancer\u2013specific mortality among men with diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Metformin use and all-cause and prostate cancer\u2013specific mortality among men with diabetes","description":"Purpose &#x2014; To evaluate the association between cumulative duration of metformin use after prostate cancer (PC) diagnosis and all-cause and","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Metformin use and all-cause and prostate cancer\u2013specific mortality among men with diabetes","og_description":"Purpose &#x2014; To evaluate the association between cumulative duration of metformin use after prostate cancer (PC) diagnosis and all-cause and","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2023-06-15T00:05:12+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\/","name":"ICES | Metformin use and all-cause and prostate cancer\u2013specific mortality among men with diabetes","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2013-08-05T04:00:00+00:00","dateModified":"2023-06-15T00:05:12+00:00","description":"Purpose &#x2014; To evaluate the association between cumulative duration of metformin use after prostate cancer (PC) diagnosis and all-cause and","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/metformin-use-and-all-cause-and-prostate-cancer-specific-mortality-among-men-with-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Metformin use and all-cause and prostate cancer\u2013specific mortality among men with diabetes"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/4073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/news_release\/7438"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6742"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6746"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6741"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6735"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6733"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/17132"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1385"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1147"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1295"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1343"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=4073"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=4073"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=4073"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=4073"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=4073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}